Acute seasonality impacting domestic growth
Muted acute season in Q2 affected legacy brands like Metrogyl and Rantac, leading to slower domestic growth. Future quarters may see similar variability.
JBCHEMICALSANDPHARMACEUT / bear-case history
Track the concerns that keep returning.
J B Chemicals · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
medium
International formulation recovery uncertainty
International formulations grew only 2% in Q2 due to subdued South Africa and US markets. Management expects high single-digit growth in H2, but recovery is not guaranteed.
ESOP charge overhang
Remaining ESOP charge of INR 47 Cr (INR 20 Cr in FY26, INR 27 Cr in FY27) will continue to impact reported profits, though excluded from operating EBITDA.
West Asia shipping disruptions
Container shipment constraints to West Asia and Asia impacted international business; Q1 remains uncertain.
CDMO execution delays
CDMO business faces delays in product development and delivery of new contracts, which could hinder growth.
Trade generics rationalization drag on India growth
Discontinuation of trade generics (7-8% of India sales) will continue to suppress reported India growth for next 3 quarters.
Field force attrition and integration challenges
Higher attrition in JB's field force and potential rationalization may disrupt sales momentum.